期刊
ALZHEIMERS & DEMENTIA
卷 12, 期 12, 页码 1273-1287出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.05.006
关键词
Alzheimer's disease; Kallikrein-8; Intraventricular antibody delivery; Ephrin receptor B2; Anxiety; Neuroplasticity; A beta pathology; A beta clearance; Autophagy; tau pathology
资金
- German Research Foundation (DFG) [HE 6823/3-1, KE 1134/7-1]
- Internal Research Funding Essen (IFORES) of the University Duisburg-Essen [D/107-81030]
Introduction: Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated in AD-affected human hippocampus. Therefore, an involvement of Kallikrein-8 in Alzheimer's pathogenesis is conceivable but remains to be proved. Methods: We determined the cerebral expression of Kallikrein-8 mRNA and protein during the course of AD in patients and in transgenic mice and tested the impact of Kallikrein-8 inhibition on AD-related pathology in mice and in primary glial cells. Results: Kallikrein-8 mRNA and protein were up-regulated in both species at incipient stages of AD. Kallikrein-8 inhibition impeded amyloidogenic amyloid-precursor-protein processing, facilitated amyloid (A beta) clearance across the blood-brain-barrier, boosted autophagy, reduced A beta load and tau pathology, enhanced neuroplasticity, reversed molecular signatures of anxiety, and ultimately improved memory and reduced fear. Discussion: Kallikrein-8 is a promising new therapeutic target against AD. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据